Dermatology

Therapies for skin conditions including atopic dermatitis, psoriasis, acne, and rare dermatological disorders.

Companies

Pipeline Drugs

1019

Key People

1033

Dermatology Pipeline (1019 drugs)

Commercial: 197Pre-clinical: 90Phase 2: 82Approved: 78Preclinical: 69Phase 3: 50Phase 1: 38Marketed: 27Not Specified: 24Development: 22Research: 15Launched: 13Phase 2b: 11Phase 1/2: 11Clinical: 11Discovery: 9Phase III: 8Unknown: 7Commercial/Development: 7Discovery/Preclinical: 7Phase 2/3: 6Phase 2a: 6Not Specified (Typically Phase 2-3): 6Validated: 6Various: 5Commercial/Ongoing Validation: 5Phase 1b: 4Filed: 4Discovery/Pre-clinical: 4Early Clinical: 4Not Applicable: 3Clinical Trials: 3Pre-clinical/Early Clinical: 3Not Disclosed: 3Research/Preclinical Tools: 3Pre-clinical/Development: 3Not Disclosed (Sponsor-led): 3Approved/Commercial: 3Research/Discovery: 3NDA Filed: 3Regulatory Review: 3Development/Launch: 3Phase II: 3Development Stage: 2Various (Typically Phase 2-4): 2Pre-clinical / Early Clinical: 2Commercial (Ingredient): 2Research/Pre-clinical: 2Pre-clinical / Exploratory: 2Commercial Launch: 2Development/Commercial: 2Undisclosed: 2Research/Assay Development: 2Lead Optimization: 2Market: 2Service: 2Ongoing Development: 2Registration: 2Commercial (licensed): 2Phase 2B: 2Pre-clinical / IND-enabling: 2NMPA Registration: 2N/A (Post-Approval): 1FDA 510(k) Cleared: 1Not Specified (Likely Phase 3/NDA): 1Clinical-Stage: 1Preclinical/Clinical-Stage: 1Screening/Diagnostic: 1Various (Typically Phase 3): 1Exploratory: 1Preclinical/Development: 1Phase 1/2a: 1Development/ANVISA Submission: 1Phase 2/3 (via licensee): 1Pre-clinical/Validation: 1Pre-clinical or Undisclosed: 1Phase 1/1b: 1Development/ANDA Submission: 1Development to Commercial: 1Pre-clinical/Research: 1Clinical Trial Launch: 1Development Stage (Pre-clinical): 1ANDA Filed/Development: 1Service Offering: 1Evidence Generation: 1FDA Qualified for Trials: 1FDA Cleared: 1Pre-Clinical: 1Discovery Lead Optimization: 1Development Candidate (DC) expected 2026: 1Development Candidate (DC) expected 2027: 1Business Development: 1Development & Commercial: 1Development/Clinical Validation: 1Development/Deployment: 1Clinical-stage: 1Development/Pre-market: 1NA: 1Approved/Clinical: 1IND-enabling: 1Pre-clinical to Commercial: 1N/A: 1Phase not specified: 1Validated/Clinical Use: 1Commercial Service: 1Development/Service: 1Pre-clinical/Proof-of-Concept: 1Approved/Phase III: 1Commercial Development: 1Clinical Research: 1Pre-clinical/Phase 1: 1Clinical-stage (Phase not specified): 1Development/Validation: 1ANDA Development / Commercial: 1Phase I-IV: 1Phase 2 (planning): 1Phase 1-2: 1Pre-IND: 1IND Filed: 1Phase 3/Pre-NDA: 1Various (Development to Approved): 1Not Specified (Early to Late-stage): 1Clinical Validation / Regulatory: 1Varies by Sponsor Protocol: 1Pre-clinical/Clinical: 1Commercial/Research: 1Not Specified (Device Pathway): 1Pre-clinical development: 1Pre-market: 1Phase 4: 1Pivotal: 1Service Expansion: 1Commercial Expansion: 1IND filed: 1Pre-clinical / Research: 1Research / Pre-clinical: 1Approved (seeking new formulation): 1Investigational: 1Development/Marketed: 1Clinical Development (phase unspecified): 1Clinical Trial: 1Discovery/Research: 1Partnership Stage: 1Phase 1/2 completed, Phase 2b upcoming: 1Concept: 1ANDA Approved: 1Launched/Phase 3: 1Research/Regulatory: 1Regulatory/Launch: 1ANDA Filed/Approved: 1Phase 3 (Preparatory): 1Phase 2 (Planned): 1ANDA Filed: 1Early Development: 1Development/Launched: 1Approved/Filed: 1Marketed/Registration: 1sNDA Submitted: 1Phase 3 Completed: 1Preclinical/Phase 1: 1Bioequivalence / Registration: 1Marketed / Lifecycle Management: 1Roll-out: 1Growth: 1Pilot: 1Feasibility Study: 1510(k) Submission: 1Feasibility Study & 510(k) Submission: 1Commercial/Early Launch: 1BLA Filed: 1Co-development Completed: 1Integration & Development: 1Agreement in Place: 1Phase 3 Ready: 1Veterinary Pilot: 1Phase 1b/2b (Planned): 1IND Cleared: 1Phase 1b/2a: 1

Drug	Company	Indication	Phase	Status
BF-200 ALA (Ameluz®)	Biofrontera	Actinic Keratosis - Pharmacokinetics	N/A (Post-Approval)	Completed
ELU42	Eluciderm	Diabetic Foot Ulcers, Burns, Open Traumatic Soft Tissue Wounds	Pre-clinical	Active
Takp-119	Akaal Pharma	Atopic dermatitis (pruritus)	Phase 2	Active
Oakp-11	Akaal Pharma	Autoimmune diseases; neuropathic pain	Phase 1	Active
ATR-12	Azitra	Netherton Syndrome	Phase 1	Active
ATR-04	Azitra	EGFR Inhibitor-Associated Rash	Preclinical	Active
ATR-01	Azitra	Ichthyosis Vulgaris	Preclinical	Active
PEP Biologic™	Intent Biologics	Diabetic Foot Ulcers	Unknown	Active
DMT310	Dermata Therapeutics	Moderate-to-Severe Acne	Phase 2b	Completed
DMT410	Dermata Therapeutics	Primary Axillary Hyperhidrosis	Phase 1b	Completed
Microcyn®/Oxum® (Rx)	Sonoma Pharmaceuticals	Advanced Wound Care	Commercial	Marketed
Seborrheic Dermatitis Program	Sonoma Pharmaceuticals	Seborrheic Dermatitis	Commercial	Marketed
Acne & Skin Irritation Program	Sonoma Pharmaceuticals	Acne, Eczema	Commercial	Marketed
Nasal & Sinus Care (Nanosyn™)	Sonoma Pharmaceuticals	Sinusitis, Allergic Rhinitis	Commercial	Marketed
Ocular Care	Sonoma Pharmaceuticals	Dry Eye, Blepharitis	Commercial	Marketed
Oral/Dental Care	Sonoma Pharmaceuticals	Gingivitis, Periodontitis	Commercial	Marketed
Veterinary Health (Oxymed®)	Sonoma Pharmaceuticals	Veterinary Wound & Skin Care	Commercial	Marketed
Surface Disinfection	Sonoma Pharmaceuticals	Environmental Disinfection	Commercial	Marketed
MOB-015	Moberg Pharma	Onychomycosis (Toenail Fungus)	Marketed	Commercial
Elyea (relugolix combo)	Organon (2)	Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis Pain	Approved	Launched / Commercial Growth
Phexxi	Organon (2)	Non-hormonal Contraceptive	Approved	Launched / Commercial Growth
Orilissa (elagolix)	Organon (2)	Endometriosis Pain	Approved	Launched / Commercial Growth
Biosimilar Aflibercept	Organon (2)	Ophthalmology (nAMD, DME)	Filed	Under Regulatory Review
Biosimilar Denosumab	Organon (2)	Osteoporosis, Bone Metastasis	Phase 3	Active
Biosimilar Ranibizumab	Organon (2)	Ophthalmology (nAMD, DME, RVO)	Phase 3	Active
Biosimilar Ustekinumab	Organon (2)	Plaque Psoriasis, Psoriatic Arthritis, IBD	Phase 3	Active
Biosimilar Bevacizumab	Organon (2)	Oncology	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Oncology	Phase 3	Active
OPN-401	Organon (2)	Recurrent Pregnancy Loss	Phase 2b	Active
INM-755	InMed Pharmaceuticals	Epidermolysis Bullosa (wound care)	Phase 2	Active
INM-088	InMed Pharmaceuticals	Glaucoma	Preclinical	Active
CANDIN	Nielsen BioSciences	HPV-associated Verruca Vulgaris (Common Warts)	Phase 3	Active
Not specified in provided content	3Sbio	Oncology	Various	Active
RYALTRIS®	glenmark	Allergic Rhinitis	Marketed	Commercialized; Direct U.S. Launch
GBR 310	glenmark	Chronic Spontaneous Urticaria / Allergic	Phase 2	Active (Novel Biologic)
GRC 39815	glenmark	COPD / Asthma	Phase 1	Active
GRC 27864	glenmark	Acute Pain	Phase 2	Active
Betadine®	iNova Pharmaceuticals	Wound Care	Commercial	Active
Biosimilar Nivolumab	Sandoz	Various Cancers (Opdivo)	Phase III	Active
Biosimilar Dupilumab	Sandoz	Atopic Dermatitis, Asthma (Dupixent)	Phase III	Active
MSC‑OA	Advancells	Osteoarthritis	Phase 1	Active
Exo‑Autism	Advancells	Autism Spectrum Disorder	Phase 1	Active
MSC‑SCI	Advancells	Spinal Cord Injury	Phase 1	Active
MSC‑Diabetes	Advancells	Type 1 Diabetes	Phase 1	Active
Dynapar AQ	Troikaa Pharmaceuticals	Post‑operative pain, intradermal diclofenac injection	Commercial	Active
Dynapar QPS	Troikaa Pharmaceuticals	Acute musculoskeletal pain, topical diclofenac	Commercial	Active
Dynapar Tablet	Troikaa Pharmaceuticals	Dental pain, diclofenac‑paracetamol fixed‑dose	Commercial	Active
Troypofol	Troikaa Pharmaceuticals	Induction of general anesthesia, propofol injection	Commercial	Active
Xykaa Extend	Troikaa Pharmaceuticals	Extended‑release analgesia, paracetamol ER	Commercial	Active
Budesonide	Coral Drugs	Respiratory disorders (asthma, COPD)	Commercial	Active